Relative adenosine production assay suitable for 2D and 3D tumor cell culture

Apple Hui Min Tay1, Andreas Lundqvist1

  • 1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

PubMed

Insights

This study introduces a new method to measure adenosine (ADO) production in tumor cells. Accurately quantifying ADO is vital for understanding its role in immune evasion and developing cancer immunotherapies.

Area of Science:

  • Immunology
  • Biochemistry
  • Cancer Biology

Background:

  • Adenosine (ADO) is an immunosuppressive metabolite crucial in purinergic signaling within the tumor microenvironment.
  • Dysregulated ADO signaling contributes to tumor immune evasion and progression.
  • Accurate measurement of ADO production is essential for therapeutic development.

Purpose of the Study:

  • To present a novel protocol for quantifying adenosine production.
  • To enable ADO level assessment in both 2D and 3D tumor cell cultures.
  • To support research into ADO's role in tumor immunology and immunotherapy.

Main Methods:

  • A competitive adenosine monophosphate (AMP) blockade strategy is employed.
  • Excessive AMP is added to inhibit CD73-mediated AMP to ADO conversion.
  • This allows for the relative quantification of ADO production.

Main Results:

  • The protocol successfully quantifies relative ADO production in cell cultures.
  • The method is applicable to both 2D and 3D tumor models.
  • Provides a reliable means to assess ADO generation under specific conditions.

Conclusions:

  • This method provides a crucial tool for researchers studying ADO in cancer.
  • Accurate ADO measurement aids in understanding tumor immune evasion mechanisms.
  • Facilitates the development of targeted immunotherapeutic strategies against cancer.

Related Concept Videos